These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 32645760)

  • 1. TERT promoter mutation analysis as a surrogate to morphology and immunohistochemistry in problematic spindle cell lesions of the urinary bladder.
    Bertz S; Stöhr R; Gaisa NT; Wullich B; Hartmann A; Agaimy A
    Histopathology; 2020 Dec; 77(6):949-962. PubMed ID: 32645760
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inflammatory myofibroblastic tumors of the urinary tract: a clinicopathologic study of 46 cases, including a malignant example inflammatory fibrosarcoma and a subset associated with high-grade urothelial carcinoma.
    Montgomery EA; Shuster DD; Burkart AL; Esteban JM; Sgrignoli A; Elwood L; Vaughn DJ; Griffin CA; Epstein JI
    Am J Surg Pathol; 2006 Dec; 30(12):1502-12. PubMed ID: 17122505
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Utility of a comprehensive immunohistochemical panel in the differential diagnosis of spindle cell lesions of the urinary bladder.
    Westfall DE; Folpe AL; Paner GP; Oliva E; Goldstein L; Alsabeh R; Gown AM; Amin MB
    Am J Surg Pathol; 2009 Jan; 33(1):99-105. PubMed ID: 18941404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pseudosarcomatous myofibroblastic proliferations of the urinary bladder are neoplasms characterized by recurrent FN1-ALK fusions.
    Acosta AM; Demicco EG; Dal Cin P; Hirsch MS; Fletcher CDM; Jo VY
    Mod Pathol; 2021 Feb; 34(2):469-477. PubMed ID: 32908253
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Utility of ALK-1 protein expression and ALK rearrangements in distinguishing inflammatory myofibroblastic tumor from malignant spindle cell lesions of the urinary bladder.
    Sukov WR; Cheville JC; Carlson AW; Shearer BM; Piatigorsky EJ; Grogg KL; Sebo TJ; Sinnwell JP; Ketterling RP
    Mod Pathol; 2007 May; 20(5):592-603. PubMed ID: 17396140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sarcomatoid Urothelial Carcinoma of the Bladder: Analysis of 28 Cases With Emphasis on Clinicopathologic Features and Markers of Epithelial-to-Mesenchymal Transition.
    Sanfrancesco J; McKenney JK; Leivo MZ; Gupta S; Elson P; Hansel DE
    Arch Pathol Lab Med; 2016 Jun; 140(6):543-51. PubMed ID: 27031776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted sequencing of plasmacytoid urothelial carcinoma reveals frequent TERT promoter mutations.
    Palsgrove DN; Taheri D; Springer SU; Cowan M; Guner G; Mendoza Rodriguez MA; Rodriguez Pena MDC; Wang Y; Kinde I; Ricardo BFP; Cunha I; Fujita K; Ertoy D; Kinzler KW; Bivalacqua TJ; Papadopoulos N; Vogelstein B; Netto GJ
    Hum Pathol; 2019 Mar; 85():1-9. PubMed ID: 30447301
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GATA3 expression in sarcomatoid urothelial carcinoma of the bladder.
    Fatima N; Osunkoya AO
    Hum Pathol; 2014 Aug; 45(8):1625-9. PubMed ID: 24824028
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Telomerase reverse transcriptase promoter mutations in glandular lesions of the urinary bladder.
    Vail E; Zheng X; Zhou M; Yang X; Fallon JT; Epstein JI; Zhong M
    Ann Diagn Pathol; 2015 Oct; 19(5):301-5. PubMed ID: 26239299
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ALK-1 expression in inflammatory myofibroblastic tumor of the urinary bladder.
    Tsuzuki T; Magi-Galluzzi C; Epstein JI
    Am J Surg Pathol; 2004 Dec; 28(12):1609-14. PubMed ID: 15577680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Telomerase reverse transcriptase (TERT) promoter mutation analysis of benign, malignant and reactive urothelial lesions reveals a subpopulation of inverted papilloma with immortalizing genetic change.
    Cheng L; Davidson DD; Wang M; Lopez-Beltran A; Montironi R; Wang L; Tan PH; MacLennan GT; Williamson SR; Zhang S
    Histopathology; 2016 Jul; 69(1):107-13. PubMed ID: 26679899
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inflammatory myofibroblastic tumour of the urinary bladder: the role of immunoglobulin G4 and the comparison of two immunohistochemical antibodies and fluorescence in-situ hybridization for the detection of anaplastic lymphoma kinase alterations.
    Choi E; Williamson SR; Montironi R; Zhang S; Wang M; Eble JN; Grignon DJ; Lopez-Beltran A; Idrees MT; Baldridge LA; Scarpelli M; Jones CL; Wang L; MacLennan GT; Osunkoya AO; Cheng L
    Histopathology; 2015 Jul; 67(1):20-38. PubMed ID: 25406945
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of residual tumor cells in bladder biopsy specimens: pitfalls in the interpretation of cytokeratin stains.
    Tamas EF; Epstein JI
    Am J Surg Pathol; 2007 Mar; 31(3):390-7. PubMed ID: 17325480
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cancer. TERT promoter mutations and telomerase reactivation in urothelial cancer.
    Borah S; Xi L; Zaug AJ; Powell NM; Dancik GM; Cohen SB; Costello JC; Theodorescu D; Cech TR
    Science; 2015 Feb; 347(6225):1006-10. PubMed ID: 25722414
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inflammatory myofibroblastic tumor of the bladder.
    Alderman M; Kunju LP
    Arch Pathol Lab Med; 2014 Oct; 138(10):1272-7. PubMed ID: 25268188
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TERT promoter mutation status in sarcomatoid urothelial carcinomas of the upper urinary tract.
    Wang X; Lopez-Beltran A; Osunkoya AO; Wang M; Zhang S; Davidson DD; Emerson RE; Williamson SR; Tan PH; Kaimakliotis HZ; Baldridge LA; MacLennan GT; Montironi R; Cheng L
    Future Oncol; 2017 Apr; 13(8):705-714. PubMed ID: 28052688
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunohistochemical evaluation of novel and traditional markers associated with urothelial differentiation in a spectrum of variants of urothelial carcinoma of the urinary bladder.
    Paner GP; Annaiah C; Gulmann C; Rao P; Ro JY; Hansel DE; Shen SS; Lopez-Beltran A; Aron M; Luthringer DJ; De Peralta-Venturina M; Cho Y; Amin MB
    Hum Pathol; 2014 Jul; 45(7):1473-82. PubMed ID: 24780825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High prevalence of TERT promoter mutations in micropapillary urothelial carcinoma.
    Nguyen D; Taheri D; Springer S; Cowan M; Guner G; Mendoza Rodriguez MA; Wang Y; Kinde I; VandenBussche CJ; Olson MT; Ricardo BF; Cunha I; Fujita K; Ertoy D; Kinzler KW; Bivalacqua TJ; Papadopoulos N; Vogelstein B; Netto GJ
    Virchows Arch; 2016 Oct; 469(4):427-34. PubMed ID: 27520411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. p-120 Catenin is a Useful Diagnostic Biomarker for Distinguishing Plasmacytoid and Sarcomatoid Variants From Conventional Urothelial Carcinoma.
    Acosta AM; Barletta J; Sonpavde G; Schnitt S; Hirsch MS
    Arch Pathol Lab Med; 2021 Aug; 145(8):1000-1008. PubMed ID: 33237989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinicopathologic features and immunophenotype of pseudosarcomatous myofibroblastic proliferation of urinary bladder].
    Zhang YH; Zhang XR; Yu J; Li HL
    Zhonghua Bing Li Xue Za Zhi; 2018 Aug; 47(8):585-590. PubMed ID: 30107662
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.